Amyotrophic lateral sclerosis screening: Difference between revisions

	Xyz Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Amyotrophic lateral sclerosis screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Amyotrophic lateral sclerosis screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Amyotrophic lateral sclerosis screening
CDC on Amyotrophic lateral sclerosis screening
Amyotrophic lateral sclerosis screening in the news
Blogs on Amyotrophic lateral sclerosis screening
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Amyotrophic lateral sclerosis screening

VisualWikitext

Revision as of 19:42, 28 September 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:

[Condition 1]
[Condition 2]
[Condition 3]

References

Template:WH Template:WS

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{Xyz}}
-{{Amyotrophic lateral sclerosis}}
+{{CMG}}; {{AE}} {{MMJ}}
+==Overview==
-Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
+There is insufficient evidence to recommend routine screening for [disease/malignancy].
+OR
+According to the [guideline name], screening for [disease name] is not recommended.
+OR
+According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
+==Screening==
+There is insufficient evidence to recommend routine screening for [disease/malignancy].
+OR
+According to the [guideline name], screening for [disease name] is not recommended.
+OR
+According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
+*[Condition 1]
+*[Condition 2]
+*[Condition 3]
 ==References==
 {{Reflist|2}}
-[[Category:Needs content]]
+{{WH}}
-[[Category:Motor neuron disease]]
+{{WS}}
-[[Category:Neurology]]
+[[Category: (name of the system)]]
-[[Category:Disease]]

Amyotrophic lateral sclerosis screening: Difference between revisions

Revision as of 19:42, 28 September 2018

Overview

Screening

References

Navigation menu